Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Luminex, BD, Seegene, and More

NEW YORK (GenomeWeb) – Luminex said this week that its board of directors has declared a cash dividend for the second quarter of 2017 of $.06 per common share, payable on July 14 to shareholders of record on June 23.

Becton Dickinson this week declared a quarterly dividend of $.73 per common share, payable on June 30 to shareholders of record on June 9.

Seegene said this week that it will collaborate with Thermo Fisher Scientific to file for US Food and Drug Administration approval of their respective molecular diagnostic products. Specifically, Seegene plans to file for FDA clearance of its Allplex assay portfolio in parallel with Thermo Fisher filing for FDA clearance of its QuantStudio 5 real-time PCR system. A Seegene spokesperson said that the company will optimize and validate its portfolio of multiplex, syndromic panel qPCR assays on Thermo's QS5, and each company will incur the cost of and responsibility of filing for their respective products. Seegene said it aims to file for 510(k) clearance by the end of 2018. In a statement, a Thermo Fisher spokesperson noted that the partnership "is in line with our strategic initiative to develop and deliver diagnostic tools from our genetic analysis portfolio to the market, either through development of our own content for our platforms or in collaboration with global assay developers."

Premaitha Health said this week that its CE-marked non-invasive prenatal Iona test has been validated for use on Thermo Fisher Scientific’s Ion S5 range of instruments. Its validation, done in partnership with Thermo Fisher, will potentially broaden Premaitha’s laboratory customer base. With the validation, the Iona test presents a potential NIPT solution for use with the Ion S5 instrument's growing network of laboratories, Premaitha said, adding that Ion S5 is being widely adopted globally by laboratories conducting next-generation DNA sequencing.

Mesa Biotech this week received ISO 13485:2003 certification, moving the firm closer to commercializing its Accula point-of-care diagnostic system in the US and EU. ISO 13485:2003 specifies the quality requirements needed to demonstrate medical devices and related services meet customer and regulatory requirement. The Accula system consists of a portable, palm-sized dock and a disposable, assay-specific test cassette.

The tranSMART and i2b2 foundations announced this week that they have completed their merger to become the i2b2 tranSMART Foundation, a global non-profit foundation facilitating the development of precision medicine. The foundation has also established a partnership program to engage the corporate, non-profit, and academic communities to advise, sponsor and participate in the development of the projects being executed by the foundation.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.